Webinar Thursday, September 15, 2022

To receive continuing education (CE) for WC4520-091522—Clinician Outreach and Communication Activity (COCA) Calls/Webinars—2022-2023 Recommendations for Influenza Prevention and Treatment in Children: An Update for Pediatric Providers, Thursday, September 15, 2022, please visit TCEO and follow these 9 Simple Steps by Monday, October 17, 2022.

To receive continuing education (CE) for WD4520-091522—Clinician Outreach and Communication Activity (COCA) Calls/Webinars—2022-2023 Recommendations for Influenza Prevention and Treatment in Children: An Update for Pediatric Providers, Thursday, September 15, 2022, (Web on Demand), please visit TCEO and follow these 9 Simple Steps between Tuesday, October 18, 2022, and Friday, October 18, 2024.

In support of improving patient care, the Centers for Disease Control and Prevention is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.

CME: The Centers for Disease Control and Prevention designates this activity for a maximum of 1 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

AAPA CME: The Centers for Disease Control and Prevention has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 1 AAPA Category 1 CME credits. Approval is valid until 12/13/2023. PAs should only claim credit commensurate with the extent of their participation

CNE: The Centers for Disease Control and Prevention designates this activity for 1 nursing contact hours.

CPE: The Centers for Disease Control and Prevention designated this (Knowledge-based) event for pharmacists to receive 0.1 CEUs in pharmacy education. The Universal Activity Number is JA4008229-0000-22-108-L04-P and enduring is JA4008229-0000-22-109-H04-P. 

Once credit is claimed, an unofficial statement of credit is immediately available on TCEOnline. Official credit will be uploaded within 60 days on the NABP/CPE Monitor.

CEU: The Centers for Disease Control and Prevention is authorized by IACET to offer 0.1 CEU’s for this program.

CECH: Sponsored by the Centers for Disease Control and Prevention, a designated provider of continuing education contact hours (CECH) in health education by the National Commission for Health Education Credentialing, Inc. This program is designated for Certified Health Education Specialists (CHES^®) and/or Master Certified Health Education Specialists (MCHES^®) to receive up to 1.0 total Category I continuing education contact hours. Maximum advanced level continuing education contact hours available are 1. Continuing Competency credits available are 1. CDC provider number 98614.

AAVSB/RACE: This program was reviewed and approved by the AAVSB RACE program for 1.0 hours of continuing education. Participants should be aware that some boards have limitations on the number of hours accepted in certain categories and/or restrictions on certain methods of delivery of continuing education. Please contact the AAVSB RACE program at race@aavsb.org if you have any comments/concerns regarding this program’s validity or relevancy to the veterinary profession.

For Certified Public Health Professionals (CPH): The Centers for Disease Control and Prevention is a pre-approved provider of Certified in Public Health (CPH) recertification credits and is authorized to offer 1 CPH recertification credits for this program.

DISCLOSURE: In compliance with continuing education requirements, all planners and presenters must disclose all financial relationships, in any amount, with ineligible companies over the previous 24 months as well as any use of unlabeled product(s) or products under investigational use.

CDC, our planners, and presenters wish to disclose they have no financial relationship(s) with ineligible companies whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients, with the exception of Dr. Kristina Bryant who is an investigator on clinical trials with Gilead, Enanta, and Pfizer.

All of the relevant financial relationships listed for these individuals have been mitigated.

Content will not include any discussion of the unlabeled use of a product or a product under investigational use, with the exception of Dr. Fatimah Dawood’s discussion of neuraminidase inhibitor medications (antivirals) that are FDA approved only for the treatment of uncomplicated influenza but will discuss off-label use such as for hospitalized patients or for unapproved age groups such as young neonates.

CDC did not accept financial or in-kind support from ineligible companies for this continuing education activity.